You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 297 No. 11, March 21, 2007 TABLE OF CONTENTS
  JAMA
  •  Online Features
  This Week in JAMA
 This Article
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

This Week in JAMA

JAMA. 2007;297:1163.

CV Event Rates in Outpatients at Risk

In an analysis of data from the Reduction of Atherothrombosis for Continued Health (REACH) Registry, an international prospective cohort of patients with established atherosclerotic arterial disease or at least 3 risk factors for atherothrombosis, Steg and REACH Registry coinvestigators (SEE ARTICLE) assessed 1-year rates of cardiovascular (CV) death, myocardial infarction, and stroke in outpatients. The investigators found high 1-year rates of CV events. Event rates were 2 to 3 times higher among patients with established disease vs those with risk factors only, and these rates were increased among patients with symptomatic disease in multiple locations. In an editorial, McDermott (SEE ARTICLE) discusses the increasing burden of chronic cardiovascular disease.


Secondary Neoplasms After Childhood ALL

Secondary neoplasms are a concern among long-term survivors of cancer therapy. Hijiya and colleagues investigated the incidence and characteristics of secondary neoplasms in a cohort of patients who were treated for childhood acute lymphoblastic leukemia (ALL) between 1962 and 1998 and had a median follow-up time of 18.7 years. The authors report that the cumulative incidence of secondary neoplasms was 4.17% (SE, 0.46%) at 15 years and increased to 10.85% (SE, 1.27%) at 30 years of follow-up, representing a significantly increased risk compared with that of the general population.


Figure 70007FA

(SEE ARTICLE)


Payments to Physicians by Pharmaceutical Companies

Five states and the District of Columbia have mandated disclosure of pharmaceutical company payments to physicians. Ross and colleagues (SEE ARTICLE) investigated the accessibility and quality of these data and the prevalence and magnitude of the payments from 2 states, Minnesota and Vermont. The authors report multiple challenges to data accessibility, including company designation of the data as "trade secrets" and missing data. Payments to physicians often exceeded the $100 maximum recommended by professional organizations. In an editorial, Brennan and Mello (SEE ARTICLE) discuss how the study findings may further undermine public trust in the pharmaceutical industry and regulatory efforts.


Trends in Black-White Life Expectancy Gap in the US

Life expectancy at birth is lower for blacks than whites and in the past several decades, this black-white "gap" increased and then declined for reasons not yet explained. Harper and colleagues analyzed national vital statistics data from 1983 to 2003 to examine the contribution of specific age groups and causes of death to changes in the black-white life expectancy gap. Among the authors' findings were that increased mortality among blacks from human immunodeficiency virus (HIV) and heart disease widened the gap between 1983 and 1993, and declines since 1993 can be attributed to mortality improvements in homicide, HIV, unintentional injuries, and, among women, heart disease.

(SEE ARTICLE)


Eligibility Criteria of Randomized Controlled Trials

Selective eligibility criteria are central to the feasibility and internal validity of randomized controlled trials (RCTs) but may compromise the generalizability of the trial results. Van Spall and colleagues conducted a systematic review of RCTs published between 1994 and 2006 and found that common medical conditions, age, concomitant medications, and female sex were frequent exclusion criteria. Exclusions were particularly common in drug intervention trials and often were not justified in the context of the trial.

(SEE ARTICLE)


A Piece of My Mind

"Maybe we should talk about putting methods in place to attract those students who enter medicine because they care, not because they can." From "Endangered Species."

(SEE ARTICLE)


Medical News & Perspectives

Spurred by concerns about a potential pandemic arising from H5N1 avian influenza, experts are working to establish effective pandemic preparedness strategies at the national, state, and local levels.

(SEE ARTICLE)


CLINICIAN'S CORNER
Late vs Early Umbilical Cord Clamping

In a systematic review and meta-analysis of clinical trials, Hutton and Hassan (SEE ARTICLE) found that in full-term infants, a 2-minute delay in umbilical cord clamping is associated with improved hematologic status. In an editorial, Oh (SEE ARTICLE) discusses implications of this finding for clinical practice.


Audio Commentary

Dr DeAngelis summarizes and comments on this week's issue. Go to http://jama.ama-assn.org/misc/audiocommentary.dtl.


JAMA Patient Page

For your patients: Information about acute lymphoblastic leukemia.

(SEE ARTICLE)



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.